Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04922593 · ClinicalTrials.gov registry record · Phase 1
Relative Bioavailability of LY03010 Compared to Listed Drug
A Phase 1 study of Schizophrenia and Mood Disorders, sponsored by Luye Pharma Group.
- Completed
- Registry status
- Phase 1
- Development phase
- 281
- Enrollment target
- 9
- Study locations
NCT04922593 is a Phase 1 study of Schizophrenia and Mood Disorders that has completed, run by Luye Pharma Group. The registered enrollment target is 281 participants, above the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (29% higher). The trial reports 9 study locations across 5 states.
The verdict
NCT04922593, a Phase 1 study of Schizophrenia and Mood Disorders, has completed, sponsored by Luye Pharma Group.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 281 participants
- Enrollment target
- 9
- Study locations
Study Summary
This is a randomized, multiple-dose, open-label, parallel-group study. Subjects will undergo screening evaluations to determine eligibility within 28 days prior to study drug administration. Approximately 280 eligible subjects will be randomized in a 1:1 ratio into 1 of 2 treatment groups. Subjects will be admitted to the clinical facilities the day before dosing (Day 0), and will be randomized and receive the first dosing on Day 1. Subjects will stay at site till Day 2 after PK collection. All subjects will return to the clinical sites at designated study days for dosing, PK sample collections and assigned clinical activities. All subjects randomized to LY03010 treatment group will receive the first dose of 351 mg LY03010 by IM injection on Day 1 in the deltoid muscle, followed by five (5) monthly dosing of 156 mg LY03010 in the gluteal muscle with the last dose on Day 141. All subjects randomized to SUSTENNA treatment group will receive the first dose of 234 mg SUSTENNA by IM injection on Day 1 in the deltoid muscle, and a second IM dose of 156 mg SUSTENNA on Day 8 in the deltoid muscle, followed by five (5) monthly IM dosing of 156 mg of SUSTENNA in the gluteal muscle with the last dose on Day 148. End of Study (EOS) visit for LY03010 treatment group will be on Day 169, 28 days after last dosing day; End of Study for SUSTENNA treatment group will be on Day 176, 28 days after last dosing. At EOS visit, subjects will complete the study after a series of assigned clinical assessments. A 30-day follow up call will be conducted by the clinical research staff to ensure participant's well-being.
Conditions Studied
Interventions
- DRUG LY03010; paliperidone palmitate
- DRUG INVEGA SUSTENNA
Study Locations (9)
California
- Collaborative Neuroscience Network, Inc. - Garden Grove
- Synergy San Diego - Lemon Grove
- CNS Network, LLC - Torrance
New Jersey
- Hassman Research Institute - Berlin
- Hassman Research Institute - Marlton
Texas
- InSite Clinical Research, LLC - DeSoto
- Pillar Clinical Research, LLC - Richardson
Florida
- Innovative Clinical Research, Inc. - Miami Lakes
Illinois
- Uptown Research Institute, LLC - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 281 participants |
| Start Date | 2021-01-13 |
| Est. Completion | 2022-04-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04922593
The ClinicalTrials.gov registry entry for NCT04922593 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 281 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (29% higher). The listed sponsor is Luye Pharma Group, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which LY03010; paliperidone palmitate is the first listed.
NCT04922593 reports 9 study locations spanning 5 distinct geographic areas - top geographies include California, New Jersey, Texas.
Frequently Asked Questions
What is clinical trial NCT04922593 about?
NCT04922593 is a clinical study titled "Relative Bioavailability of LY03010 Compared to Listed Drug". This is a randomized, multiple-dose, open-label, parallel-group study. Subjects will undergo screening evaluations to determine eligibility within 28 days prior to study drug administration. Approximately 280 eligible subjects will be randomized in a 1:1 ratio into 1 of 2 treatment groups. Subjects ...
What is the current status of trial NCT04922593?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 281 participants. The study started on 2021-01-13. Estimated completion is 2022-04-15.
What conditions does trial NCT04922593 study?
This clinical trial studies the following conditions: Schizophrenia, Mood Disorders, Mental Disorders, Psychotic Disorders, Physiological Effects of Drugs.
What interventions are being tested in trial NCT04922593?
The interventions under investigation include: LY03010; paliperidone palmitate (DRUG), INVEGA SUSTENNA (DRUG).
Who is sponsoring clinical trial NCT04922593?
This trial is sponsored by Luye Pharma Group, which has 22 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04922593 being conducted?
This trial has 9 study locations across California, Florida, Illinois, New Jersey, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Tolerability of MDMA in Schizophrenia
RECRUITING · Phase 1
-
Imaging Synapses With [11C] UCB-J in the Human Brain
RECRUITING · Phase 1
-
A Study to Evaluate the Dose Levels, Safety, and Drug Levels of Single KarXT Intramuscular Injection in Participants With Schizophrenia
RECRUITING · Phase 1
-
Proposal To Develop A Rapid And Cost-Effective Diagnostic Test For Schizophrenia
RECRUITING · Phase 1
-
Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder
RECRUITING · Phase 1
-
Genetics of Cannabis Use Disorder and Cannabinoid Response in Humans
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.